PARD6B

Summary

PARD6B (par-6 family cell polarity regulator beta, HGNC:16245) is a protein-coding gene on chromosome 20q13.13, encoding Partitioning defective 6 homolog beta (Q9BYG5). Adapter protein involved in asymmetrical cell division and cell polarization processes. It is a selective cancer dependency (DepMap: 12.9% of cell lines).

This gene is a member of the PAR6 family and encodes a protein with a PSD95/Discs-large/ZO1 (PDZ) domain, an OPR domain and a semi-Cdc42/Rac interactive binding (CRIB) domain. This cytoplasmic protein is involved in asymmetrical cell division and cell polarization processes as a member of a multi-protein complex.

Source: NCBI Gene 84612 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 50 total
• Cancer dependency (DepMap): dependent in 12.9% of screened cell lines
• MANE Select transcript: NM_032521

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16245
Approved symbol	PARD6B
Name	par-6 family cell polarity regulator beta
Location	20q13.13
Locus type	gene with protein product
Status	Approved
Aliases	PAR-6B
Ensembl gene	ENSG00000124171
Ensembl biotype	protein_coding
OMIM	608975
Entrez	84612

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 3 protein_coding

ENST00000371610, ENST00000396039, ENST00000948561

RefSeq mRNA: 1 — MANE Select: NM_032521 NM_032521

CCDS: CCDS33485

Canonical transcript exons

ENST00000371610 — 3 exons

Exon	Start	End
ENSE00000845624	50737857	50738079
ENSE00001455648	50749659	50753741
ENSE00001455652	50731580	50731852

Expression profiles

Bgee: expression breadth ubiquitous, 223 present calls, max score 98.38.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 35.4848 / max 901.1026, expressed in 1085 samples.

FANTOM5 promoters (13 alternative TSS)

Promoter ID	TPM avg	Samples expressed
185275	15.9549	701
185273	11.2858	876
185274	2.8986	408
185266	1.5428	452
185270	0.7196	198
185272	0.6200	248
185267	0.5318	151
185271	0.5290	202
185268	0.4407	143
185269	0.3020	121

Top tissues by expression

269 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
germinal epithelium of ovary	UBERON:0001304	98.38	gold quality
renal medulla	UBERON:0000362	95.21	gold quality
pigmented layer of retina	UBERON:0001782	95.16	gold quality
palpebral conjunctiva	UBERON:0001812	93.18	gold quality
epithelium of nasopharynx	UBERON:0001951	91.54	gold quality
amniotic fluid	UBERON:0000173	91.15	gold quality
jejunal mucosa	UBERON:0000399	90.27	gold quality
lower lobe of lung	UBERON:0008949	90.10	gold quality
mucosa of paranasal sinus	UBERON:0005030	89.94	gold quality
esophagus squamous epithelium	UBERON:0006920	89.80	gold quality
bronchial epithelial cell	CL:0002328	87.30	gold quality
corpus epididymis	UBERON:0004359	86.90	gold quality
sperm	CL:0000019	86.71	gold quality
parietal pleura	UBERON:0002400	85.65	gold quality
caput epididymis	UBERON:0004358	84.70	gold quality
male germ cell	CL:0000015	83.59	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	83.56	gold quality
epithelium of esophagus	UBERON:0001976	83.26	gold quality
oral cavity	UBERON:0000167	82.88	gold quality
pleura	UBERON:0000977	82.65	gold quality
secondary oocyte	CL:0000655	82.46	gold quality
mucosa of sigmoid colon	UBERON:0004993	82.42	gold quality
colonic mucosa	UBERON:0000317	82.34	gold quality
oocyte	CL:0000023	82.11	gold quality
visceral pleura	UBERON:0002401	81.57	gold quality
metanephros cortex	UBERON:0010533	81.44	gold quality
kidney	UBERON:0002113	81.39	gold quality
cortex of kidney	UBERON:0001225	80.86	gold quality
squamous epithelium	UBERON:0006914	80.26	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	80.14	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-6678	yes	8.23
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

184 targeting PARD6B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-3163	100.00	77.23	8605
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-196A-5P	100.00	68.16	684
HSA-MIR-196B-5P	100.00	68.16	681
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-6758-5P	100.00	66.21	1470
HSA-MIR-6856-5P	100.00	65.47	1298
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-223-3P	99.99	70.14	1140
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 12.9% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 7)

• The ability of SRC family coactivators to regulate the expression of one of these genes, PARD6B/Par6, was confirmed by using cells individually depleted of SRC-1. (PMID:15677324)
• Interaction between PAR-3 and the aPKC-PAR-6 complex is indispensable for apical domain development of epithelial cells. (PMID:19401335)
• This study demonstrates that controlled regulation of PAK4 is required for apical junction formation in lung epithelial cells and highlights potential cross-talk between two Cdc42 targets, PAK4 and Par6B. (PMID:20631255)
• Data conclude that Par6B and aPKC control mitotic spindle orientation in polarized epithelia and, furthermore, that aPKC coordinately regulates multiple processes to promote morphogenesis. (PMID:21300793)
• PAK4 phosphorylates Par6B at Ser143 blocking its interaction with Cdc42. (PMID:25662318)
• found that the polarity determinants Cdc42, Par6B, PKCzeta/iota and the structural proteins ezrin and phospho-ezrin were lost from the apical membrane and accumulated either in the cytoplasm or on the basal side of enterocytes in patients (PMID:26526116)
• reduced expression of PKCzeta/Pard3/Pard6 contributes to non-small-cell lung cancer epithelial-mesenchymal transition, invasion, and chemoresistance. (PMID:28652146)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	pard6b	ENSDARG00000003865
mus_musculus	Pard6b	ENSMUSG00000044641
rattus_norvegicus	Pard6b	ENSRNOG00000010883
drosophila_melanogaster	par-6	FBGN0026192
caenorhabditis_elegans	par-6	WBGENE00003921

Paralogs (2): PARD6A (ENSG00000102981), PARD6G (ENSG00000178184)

Protein

Protein identifiers

Partitioning defective 6 homolog beta — Q9BYG5 (reviewed: Q9BYG5)

All UniProt accessions (1): Q9BYG5

UniProt curated annotations — full annotation on UniProt →

Function. Adapter protein involved in asymmetrical cell division and cell polarization processes. Probably involved in formation of epithelial tight junctions. Association with PARD3 may prevent the interaction of PARD3 with F11R/JAM1, thereby preventing tight junction assembly. The PARD6-PARD3 complex links GTP-bound Rho small GTPases to atypical protein kinase C proteins.

Subunit / interactions. Interacts with PARD3. Interacts with GTP-bound forms of CDC42 and RAC1. Interacts with GTP-bound RHOQ/TC10. Interacts with PALS1. Interacts with the N-terminal part of PRKCI and PRKCZ. Part of a complex with PARD3, CDC42 or RAC1 and PRKCI or PRKCZ. Part of a complex with LLGL1 and PRKCI. Interacts with PARD3B. Interacts with ECT2.

Subcellular location. Cytoplasm. Cell membrane. Cell junction. Tight junction.

Tissue specificity. Expressed in pancreas and in both adult and fetal kidney. Weakly expressed in placenta and lung. Not expressed in other tissues.

Domain organisation. The pseudo-CRIB domain together with the PDZ domain is required for the interaction with Rho small GTPases. The PDZ domain mediates interaction with PALS1.

Similarity. Belongs to the PAR6 family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9BYG5-1	1	yes
Q9BYG5-2	2

RefSeq proteins (1): NP_115910* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000270	PB1_dom	Domain
IPR001478	PDZ	Domain
IPR034868	PB1_Par6	Domain
IPR036034	PDZ_sf	Homologous_superfamily
IPR051741	PAR6_homolog	Family
IPR053793	PB1-like	Domain

Pfam: PF00564, PF00595

UniProt features (10 total): domain 3, region of interest 2, splice variant 2, chain 1, compositionally biased region 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BYG5-F1	70.97	0.40

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 11

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-420029	Tight junction interactions
R-HSA-9013424	RHOV GTPase cycle

MSigDB gene sets: 198 (showing top): GOBP_ESTABLISHMENT_OR_MAINTENANCE_OF_CELL_POLARITY, TGCACTT_MIR519C_MIR519B_MIR519A, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN, TATTATA_MIR374, GOBP_NEUROGENESIS, KEGG_TIGHT_JUNCTION, GOBP_CELL_JUNCTION_ORGANIZATION, MODULE_205, GOBP_REGULATION_OF_CELLULAR_LOCALIZATION, PYEON_CANCER_HEAD_AND_NECK_VS_CERVICAL_UP, GOCC_APICAL_PLASMA_MEMBRANE, GOBP_CELL_JUNCTION_ASSEMBLY, SENESE_HDAC1_TARGETS_UP, KEGG_ENDOCYTOSIS

GO Biological Process (9): cell-cell junction assembly (GO:0007043), centrosome cycle (GO:0007098), establishment or maintenance of cell polarity (GO:0007163), axonogenesis (GO:0007409), regulation of cell migration (GO:0030334), establishment or maintenance of epithelial cell apical/basal polarity (GO:0045197), cell division (GO:0051301), regulation of cellular localization (GO:0060341), protein-containing complex assembly (GO:0065003)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (15): nucleus (GO:0005634), cytosol (GO:0005829), plasma membrane (GO:0005886), bicellular tight junction (GO:0005923), cell cortex (GO:0005938), apical plasma membrane (GO:0016324), cell junction (GO:0030054), extracellular exosome (GO:0070062), tight junction (GO:0070160), PAR polarity complex (GO:0120157), cytoplasm (GO:0005737), membrane (GO:0016020), protein-containing complex (GO:0032991), apical part of cell (GO:0045177), anchoring junction (GO:0070161)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Cell-cell junction organization	1
RHO GTPase cycle	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	5
cellular process	2
cytoplasm	2
cell periphery	2
cell junction assembly	1
cell-cell junction organization	1
cell cycle process	1
microtubule organizing center organization	1
cell morphogenesis involved in neuron differentiation	1
neuron projection morphogenesis	1
axon development	1
cell migration	1
regulation of cell motility	1
establishment or maintenance of apical/basal cell polarity	1
regulation of localization	1
regulation of cellular process	1
cellular localization	1
cellular component assembly	1
protein-containing complex organization	1
binding	1
intracellular membrane-bounded organelle	1
membrane	1
apical junction complex	1
tight junction	1
apical part of cell	1
plasma membrane region	1
extracellular vesicle	1
cell-cell junction	1
serine/threonine protein kinase complex	1
intracellular anatomical structure	1
cellular_component	1
cell junction	1

Protein interactions and networks

STRING

1032 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PARD6B	CDC42	P21181	991
PARD6B	PRKCZ	Q05513	917
PARD6B	PARD3	Q8TEW0	896
PARD6B	TJP1	Q07157	671
PARD6B	LLGL2	Q6P1M3	590
PARD6B	PRKCI	P41743	583
PARD6B	SMURF1	Q9HCE7	583
PARD6B	JAM2	P57087	564
PARD6B	TIAM1	Q13009	540
PARD6B	RAC1	P15154	527
PARD6B	PARD3B	Q8TEW8	516
PARD6B	PATJ	Q8NI35	510
PARD6B	ANXA2	P07355	503
PARD6B	CRB3	Q9BUF7	494
PARD6B	RHOA	P06749	482

IntAct

176 interactions, top by confidence:

A	B	Type	Score
PARD6B	PRKCI	psi-mi:“MI:0915”(physical association)	0.960
PRKCI	PARD6B	psi-mi:“MI:0915”(physical association)	0.960
PARD6B	PRKCI	psi-mi:“MI:0914”(association)	0.960
PRKCZ	PARD6B	psi-mi:“MI:0915”(physical association)	0.950
PARD6A	PRKCI	psi-mi:“MI:0914”(association)	0.950
PARD6B	CDC42	psi-mi:“MI:0915”(physical association)	0.900
CDC42	PARD6B	psi-mi:“MI:0915”(physical association)	0.900
PRKCZ	PRKCI	psi-mi:“MI:0914”(association)	0.890
LLGL2	PRKCI	psi-mi:“MI:0915”(physical association)	0.890

BioGRID (245): PARD6B (Two-hybrid), PARD6B (Two-hybrid), PARD6B (Two-hybrid), PARD6B (Two-hybrid), PARD6B (Two-hybrid), PARD6B (Two-hybrid), PARD6B (Affinity Capture-MS), PARD6B (Affinity Capture-MS), PARD3 (Affinity Capture-MS), LLGL2 (Affinity Capture-MS), PTPN14 (Affinity Capture-MS), LLGL1 (Affinity Capture-MS), ZZEF1 (Affinity Capture-MS), WWC1 (Affinity Capture-MS), PRKCZ (Affinity Capture-MS)

ESM2 similar proteins: A1A5R8, A1L1R5, A2A3K4, A2VDZ4, A5PKL1, A7E379, A8KBE0, B2GUY1, B2RC85, E1B9D8, E9PYQ0, O00444, O00522, O01326, O54852, P0C881, P59111, Q04688, Q08CH7, Q14693, Q1JPG1, Q5R9Z7, Q5RFV8, Q61XX9, Q64702, Q66HB5, Q68FF0, Q6DTM3, Q6EEF3, Q6EMB2, Q6NSI8, Q6S5J6, Q6TNJ1, Q6ZT98, Q8BRB7, Q8CDA1, Q8CDM1, Q8CDP0, Q8K3E5, Q8N157

Diamond homologs: A0A8C0TYJ0, A0A8P0N4K0, A5PKA5, F1MCA7, G5ECY0, O14907, O14910, O35274, O35867, O55164, O61967, O62674, O62675, O62676, O88951, O88952, P31016, P57105, P70175, P70587, P78352, P97879, Q0P5E6, Q0P5F3, Q12959, Q13424, Q13425, Q13884, Q14160, Q15599, Q22638, Q28626, Q28C55, Q2KIB6, Q32LE7, Q32LM6, Q3T0C9, Q3UHD6, Q4H4B6, Q5EBL8

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 82 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Translocation of SLC2A4 (GLUT4) to the plasma membrane	5	13.5×	4e-03

GO biological processes:

GO term	Partners	Fold	FDR
establishment or maintenance of epithelial cell apical/basal polarity	7	54.2×	3e-08
establishment or maintenance of cell polarity	6	32.1×	9e-06
establishment of cell polarity	6	30.6×	9e-06
small GTPase-mediated signal transduction	6	14.7×	6e-04
transmembrane transport	5	11.2×	6e-03
regulation of actin cytoskeleton organization	5	10.5×	7e-03
actin filament organization	6	9.5×	4e-03
intracellular protein localization	6	8.4×	6e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

50 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	37
Likely benign	1
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

541 predictions. Top by Δscore:

Variant	Effect	Δscore
20:50737854:TAGT:T	acceptor_loss	1.0000
20:50737855:A:AG	acceptor_gain	1.0000
20:50737855:AGTTT:A	acceptor_gain	1.0000
20:50737856:G:GA	acceptor_gain	1.0000
20:50737856:GT:G	acceptor_gain	1.0000
20:50737856:GTTT:G	acceptor_gain	1.0000
20:50737856:GTTTG:G	acceptor_gain	1.0000
20:50738075:GAAGG:G	donor_gain	1.0000
20:50738079:GGT:G	donor_loss	1.0000
20:50738080:G:GG	donor_gain	1.0000
20:50738080:GT:G	donor_loss	1.0000
20:50738081:T:A	donor_loss	1.0000
20:50731838:G:GT	donor_gain	0.9900
20:50731850:AAGGT:A	donor_loss	0.9900
20:50731851:AGG:A	donor_loss	0.9900
20:50731853:G:GA	donor_loss	0.9900
20:50738076:AAGG:A	donor_gain	0.9900
20:50738078:GG:G	donor_gain	0.9900
20:50738079:GG:G	donor_gain	0.9900
20:50738082:AAGTA:A	donor_loss	0.9900
20:50738083:AGTAT:A	donor_loss	0.9900
20:50749657:A:AG	acceptor_gain	0.9900
20:50749658:G:GG	acceptor_gain	0.9900
20:50749658:GAA:G	acceptor_gain	0.9900
20:50731848:GCAAG:G	donor_gain	0.9800
20:50737832:A:G	acceptor_gain	0.9800
20:50737854:T:G	acceptor_gain	0.9800
20:50737856:GTT:G	acceptor_gain	0.9800
20:50738077:AGG:A	donor_gain	0.9800
20:50738078:GGG:G	donor_gain	0.9800

AlphaMissense

2469 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
20:50731846:G:C	K20N	1.000
20:50731846:G:T	K20N	1.000
20:50731847:A:C	S21R	1.000
20:50731849:C:A	S21R	1.000
20:50731849:C:G	S21R	1.000
20:50737869:T:C	F27L	1.000
20:50737870:T:C	F27S	1.000
20:50737871:T:A	F27L	1.000
20:50737871:T:G	F27L	1.000
20:50737872:C:A	R28S	1.000
20:50737873:G:C	R28P	1.000
20:50737875:C:G	R29G	1.000
20:50737878:T:C	F30L	1.000
20:50737879:T:C	F30S	1.000
20:50737880:T:A	F30L	1.000
20:50737880:T:G	F30L	1.000
20:50737918:T:C	F43S	1.000
20:50737930:T:C	L47P	1.000
20:50737941:C:G	H51D	1.000
20:50737999:T:C	L70P	1.000
20:50738005:T:A	I72K	1.000
20:50738005:T:C	I72T	1.000
20:50738005:T:G	I72R	1.000
20:50738022:T:G	Y78D	1.000
20:50738031:G:C	A81P	1.000
20:50738032:C:A	A81D	1.000
20:50738056:T:A	L89H	1.000
20:50738056:T:C	L89P	1.000
20:50749784:T:C	F139L	1.000
20:50749786:T:A	F139L	1.000

dbSNP variants (sampled 300 via entrez): RS1000236645 (20:50752891 G>A,T), RS1000319496 (20:50731572 G>A), RS1000518289 (20:50731523 C>G), RS1000557746 (20:50737373 A>G,T), RS1000939239 (20:50737120 CTTCCTCCCCA>C), RS1000964714 (20:50754172 C>T), RS1000991593 (20:50736817 C>T), RS1001202877 (20:50745746 G>A), RS1001279534 (20:50743434 A>C), RS1001311750 (20:50730944 G>A,C), RS1001471238 (20:50749472 C>G), RS1001642921 (20:50751740 T>G), RS1001653247 (20:50734126 A>C), RS1001763295 (20:50740520 G>A), RS1001884416 (20:50742055 GTGTTT>G,GTGTTTTGTTT)

Disease associations

OMIM: gene MIM:608975 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST001164_2	Bipolar disorder	3.000000e-06

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

50 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, increases expression	4
trichostatin A	affects cotreatment, decreases expression	3
ochratoxin A	increases expression, decreases expression	2
Air Pollutants	increases abundance, affects expression, affects cotreatment, decreases expression	2
Ozone	increases abundance, affects expression, affects cotreatment, decreases expression	2
Valproic Acid	affects cotreatment, decreases expression	2
aristolochic acid I	decreases expression	1
methylmercuric chloride	decreases expression	1
alpha-pinene	decreases expression, increases abundance, affects cotreatment	1
bis(tri-n-butyltin)oxide	increases expression	1
bisphenol A	increases expression	1
testosterone undecanoate	affects cotreatment, decreases expression	1
2-methyl-4-isothiazolin-3-one	increases expression	1
tributyltin	increases expression	1
cobaltous chloride	increases expression	1
methylmercury II	increases expression	1
methacrylaldehyde	increases abundance, affects cotreatment, decreases expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
abrine	increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone	increases phosphorylation	1
asparanin A	decreases expression	1
jinfukang	decreases expression	1
NSC 689534	affects binding, increases expression	1
Sunitinib	decreases expression	1
Leflunomide	increases expression	1
Acrolein	affects cotreatment, decreases expression, increases abundance	1
Amphotericin B	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.